Archive for the ‘Ethical, legal and social issues’ Category

Right Turn: My question to Paul Knoepfler: Do you ever sleep?

Author: Stacey Johnson, 03/10/17

Paul Knoepfler, already well known for his prolific blogging at The Niche and for his role as a stem cell educator and tireless patient advocate – award winning no less – has taken on another project. Ask him a question about stem cells and you may get a live response. On February 26th, Dr. Knoepfler,…Read more

Interspecies generation of insulin producing cells now a reality

Author: David Kent, 03/01/17

From science fiction novelists through to medical doctors and industry leaders, a huge amount of attention has been given to the idea of growing human organs for transplantation in large farm animals like pigs and sheep. The need for organs to transplant into patients is one driving motivation (~5000 patients waiting in Canada alone), but…Read more

Ending on a high note – Day 3 of TMM2016

Author: Camila Londono, 10/31/16

Though the last day of the Till and McCulloch Meetings was a short one, it was absolutely fantastic. The day began with a thought-provoking talk by Douglas Sipp, from the Riken Center for Developmental Biology, touching upon the many issues surrounding regulation of stem cell therapies. I think as scientists, we often tend to forget…Read more

Lobbying for deregulation of stem cell procedures is giving rise to a new “dark economy”

Author: Hamideh Emrani, 10/31/16

Day 3 of the Till & McCulloch Meetings continued with many interesting talks. The one that I have chosen to write about in more detail Dr. Douglas Sipp’s, titled “The Stem Cell Dark Economy.” I think his talk was really thought provoking, and important to be shared with our readers. He began with an old…Read more

Challenging assumptions to expand our thinking? Insights from Session 1 of TMM2016

Author: Camila Londono, 10/25/16

The fifth Till & McCulloch Meetings started off with a bang, with an incredibly exciting and provocative talk by Dr. Sara-Jane Dunn that highlighted the predictive power of Boolean network models. Dr. Dunn, who works at Microsoft Research, introduced the idea of biological computation: a cell’s gene expression “decision making” can be modelled using Boolean…Read more

STEMinism: Chasing diversity and equality in STEM

Author: Camila Londono, 10/14/16

On October 11 I attended SHE DID THAT, the Ada Lovelace event, held at the University of Toronto, that Samantha Payne wrote about in Signals earlier this week. It was an exciting evening that not only celebrated incredible women in science, but also served as a reminder that we have a long way to go…Read more

Ada Lovelace Day: celebrating women in STEM

Author: Samantha Payne, 10/11/16

Can you name five historically influential women in the STEM fields (science, technology, engineering and medicine)? What about three? I recently asked myself this question and found that I struggled to come up with names, despite the formal training I’ve received in science at both the undergraduate and graduate level. Yet there are many: from…Read more

Right Turn: Finding donors for multi-ethnic patients with rare blood diseases

Author: Guest, 10/07/16

Laine Jaremey is the Communications Specialist at CCRM. Laine has over eight years of experience as a strategic communicator with a focus in the health industry. She completed her Bachelor’s Degree in Communication Studies at Wilfrid Laurier University, and a Postgraduate certificate in Public Relations from Humber College. Follow her on Twitter @LaineJaremey Being diagnosed with…Read more

Would you buy a designer bag made from lab-grown human skin?

Author: Jovana Drinjakovic, 10/06/16

In case you haven’t heard, Tina Gorjanc, a UK-based fashion designer, shocked the fashion world this summer when she announced her Pure Human collection of luxury leather items, to be made from lab-grown human skin, engineered with the late designer Alexander McQueen’s DNA. I know, it makes your brain twist in on itself! As you…Read more

Right Turn: “Comic” twist on CRISPR

Author: Lisa Willemse, 09/30/16

There’s nothing really funny about the patent debate on CRISPR-Cas9 gene editing. It’s been a contentious and expensive court battle, that has thankfully steered clear of mud-slinging (mostly). Which is good, since there’s more than enough of that in the U.S. these days, thanks to the Donald. For those who have followed the CRISPR patent…Read more